Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
Status:
Completed
Trial end date:
2020-12-23
Target enrollment:
Participant gender:
Summary
This study is designed to compare the incidence of infusion reactions to treatment with an
anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with
intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during
first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or
Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan®
(rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions
while on maintenance or retreatment.